2019
DOI: 10.1016/j.colsurfb.2019.03.057
|View full text |Cite
|
Sign up to set email alerts
|

In Situ In Vivo radiolabeling of polymer-coated hydroxyapatite nanoparticles to track their biodistribution in mice

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
14
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
7
1

Relationship

2
6

Authors

Journals

citations
Cited by 15 publications
(14 citation statements)
references
References 35 publications
0
14
0
Order By: Relevance
“…We speculate that the main reason for the increase in HAP size is due to the agglomeration effect and not Pip loading or coating. After injection of the particles in vivo they are distributed in different organs depending on the different routes of in vivo application: sub-cutaneous, intramuscular, and intravenous injection [60,61]. Therefore, for future in vivo studies, the selection of intra-muscular, intradermal, or subcutaneous depot will be needed in order to avoid the barrier made by the reticulo-endothelial system (RES).…”
Section: Discussionmentioning
confidence: 99%
“…We speculate that the main reason for the increase in HAP size is due to the agglomeration effect and not Pip loading or coating. After injection of the particles in vivo they are distributed in different organs depending on the different routes of in vivo application: sub-cutaneous, intramuscular, and intravenous injection [60,61]. Therefore, for future in vivo studies, the selection of intra-muscular, intradermal, or subcutaneous depot will be needed in order to avoid the barrier made by the reticulo-endothelial system (RES).…”
Section: Discussionmentioning
confidence: 99%
“…According to these results, 177 Lu-DOTA-HA-PLGA-MTX NPs are a promising agent to treat rheumatic arthritis (Trujillo-Nolasco et al., 2019 ). Another study evaluated the biodistribution of hydroxyapatite (HA) PHPMA-TT NPs radiolabeled (Lobaz et al., 2019 ). They compared the biodistribution of 99m Tc-HEDP with 99m Tc-HEDP HAP NPs.…”
Section: Radioactive Polymeric Nanoparticles For Imaging and Therapymentioning
confidence: 99%
“…It was observed that 99m Tc-HEDP accumulated in the liver and bones, while 99m Tc-HEDP HAP NPs accumulated in the liver and spleen. Besides, HAP NPs labeled in vitro or in vivo with 99m Tc-HEDP had same distribution profile (Lobaz et al., 2019 ).…”
Section: Radioactive Polymeric Nanoparticles For Imaging and Therapymentioning
confidence: 99%
“…Hydroxyapatite (HAP) NPs are known to be biodegradable and biocompatible as HAP is the mineral component of bones. Geminal hydroxyalkylidene diphosphonates possess excellent affinity to HAP [ 23 ] and number of other inorganic nanoparticles [ 24 ] due to their structural similarity to diphosphate, which is present in the crystal lattice of HAP. Radiolabeled hydroxyalkylidene diphosphonates therefore accumulate in bones and are used as bone-seeking radiodiagnostics for bone metastases, fractures and sites of bone remodeling in general [ 25 ].…”
Section: Introductionmentioning
confidence: 99%
“…Recently, we published a comparison of antitumor efficacy of poly[ N -(2-hydroxypropyl)methacrylamide]-based and poly(2-ethyl-2-oxazoline)-based doxorubicin delivery systems in in vivo animal tumor models [ 26 ]. We also reported that HAP NPs can be coated with hydrophilic biocompatible polymers using terminal hydroxybisphosphonate groups and efficiently radiolabeled even in situ and in vivo in healthy mice with commercially available bone-seeking radiopharmaceuticals such as 99m Tc-hydroxyethylidene diphosphonate ( 99m Tc-HEDP) [ 23 ]. The main purpose of this study is to head-to-head compare biological behavior (blood circulation time, biodistribution including solid tumor and organ accumulation and biodegradation) of three leading polymers used as coating materials for biocompatibilization of NPs.…”
Section: Introductionmentioning
confidence: 99%